Prostate cancer screening: a new way forward or another false start?
- 19 August 2021
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Urology
- Vol. 18 (10) , 579-580
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- MRI-Targeted or Standard Biopsy in Prostate Cancer ScreeningNew England Journal of Medicine, 2021
- The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screeningBJU International, 2021
- Reconsidering Prostate Cancer Mortality — The Future of PSA ScreeningNew England Journal of Medicine, 2020
- Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 YearsJAMA Network Open, 2020
- Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociNature Genetics, 2018
- Prostate-Specific Antigen–Based Screening for Prostate CancerJAMA, 2018
- Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic studyThe Lancet Oncology, 2015
- Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate CancerEuropean Urology, 2015
- Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trialThe Lancet Oncology, 2014
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991